Scientists uncover mechanism allowing bacteria to survive the human immune system
Researchers have uncovered molecular details of how pathogenic bacteria fight back against the human immune response to infection.
List view / Grid view
Researchers have uncovered molecular details of how pathogenic bacteria fight back against the human immune response to infection.
Over 10 million units of platelets are transfused worldwide each year in one of the most common procedures in clinical medicine. However, platelets derived from human donors can transmit infections and trigger serious immune reactions that eventually render the therapy ineffective (a condition known as alloimmune refractoriness). In addition, since…
The Zika virus, which is spread to people primarily through the bite of an infected Aedes species mosquito, is an impending threat to America’s borders, with over 5000 cases now reported in the continental US. Zika virus infection has been associated with Guillain-Barré Syndrome, and infection during pregnancy has been…
Scientists will develop and test promising new molecules for targeting RAS, one of the most common driving mutations in aggressive, hard to treat cancers including pancreatic and lung cancer.
The successful combination of two therapies results in the growth of specialised vessels that deliver cancer-fighting immune cells to a tumour, potentially leading to more effective treatments and longer survival periods.
Over 90 million blood transfusions are carried out worldwide each year and alternative sources to donor-derived blood are being sought to meet rising demand. In addition there is a need to secure a safer supply of blood products, chiefly in developing countries where there is a relatively higher risk of…
Biochemist and physician Professor Ivan Dikic and microbiologist Professor Volker Müller are very honoured that their pioneering research projects have been selected for this substantial financial support.
New findings could help to extend the lives of patients suffering from one of the most common types of brain tumours - low-grade glioma.
Polyphor Ltd, a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases, has completed a CHF 40 million private placement. Exisiting Polyphor investors contributed to 98% of the financing.
Using state-of-the-art gene editing technology, scientists have discovered a promising target to treat atypical teratoid/rhabdoid tumour (AT/RT) - a highly aggressive and therapy resistant brain tumour that mostly occurs in infants.
Neonatal diabetes mellitus (NDM), or diabetes among infants less than six months of age, is a rare form of diabetes caused by a mutation in genes crusial to the development or function of beta cells. In about half of such cases, the disease becomes permanent (PNDM). Mutations in more than…
BenevolentAI, a British artificial intelligence company, has partnered with MRC Technology (MRCT), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
Scientists unveil the complex molecular structure that causes lethal infections by Mycobacterium tuberculosis (Mtb). Their findings might have implications for potential therapies against antibiotic-resistant tuberculosis.
Head trauma is a common injury, and according to several scientific studies, undiagnosed concussion may lead to devastating outcomes and a premature neurodegenerative condition.
The new centre will serve as one of the world’s leading institutes for conducting and coordinating research about cannabinoids, endocannabinoids and medical Cannabis. In addition, it will promote collaboration and disseminate information.